GLP-1 RA for Stage 1 Type 1 Diabetes

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

NCT Number	NCT07430332
Lead Sponsor	Children's Hospital Medical Center, Cincinnati
Conditions	Stage 1 Diabetes Mellitus, Type 1
Enrollment	15 participants
Start Date	2027-09-01
Primary Completion	2029-06-01 (estimated)
Study Completion	2030-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-24